Indivior is closely monitoring developments relating to COVID-19 (novel coronavirus) outbreak.
Our priority remains the ongoing supply of medicines to healthcare providers and patients, the health and safety of our employees and the well-being of the patients we serve.
We are actively managing our global supply chains to minimize any potential disruption. Our executive management and supply team are together working with internal and external business partners and regulatory authorities to assess and mitigate the potential impact of COVID-19. We are committed to helping ensure that patients will continue to have an ongoing supply of their medication. Based on our assessment and environment we do not currently expect to have any material supply interruptions.
We are also following guidelines provided by international health authorities and all global, national and local government mandates regarding measures to keep our workforce and communities safe. We have instituted a remote work policy for office and field-based staff leveraging all available technology to ensure essential activities will continue to provide patients, healthcare providers and other key stakeholders with the supports they need.
We will continue to monitor the situation closely, placing the needs of patients first at all times.
Share